Treatment of allergic diseases includes allergen avoidance, pharmacotherapy, allergen vaccine specific immunotherapy, and patient education. Allergen vaccine-specific immunotherapy (SIT) is an allopathic treatment that can affect the immune mechanism of allergic diseases, thus altering their natural course and having a curative effect. Early treatment has the potential to cure allergic diseases. Indications: 1. Patients with clinically diagnosed allergic asthma or rhinitis/conjunctivitis; 2. Patients with positive skin tests for clinically relevant allergens; 3. Patients with elevated specific IgE antibodies to clinically relevant allergens; 4. Patients for whom drug therapy is not sufficient to control symptoms or who experience intolerable side effects; 5. Patients who do not wish to receive drug therapy. Clinical advantages: 1. Reduction or elimination of allergic asthma (or rhinitis) symptoms; 2. Reduction in the chance of allergic rhinitis developing into asthma; 3. Reduction or even discontinuation of allopathic medication doses; 4. Normalization of the immune system with long-lasting efficacy; 5. Significant improvement in quality of life and reduction in medical costs through reduction in allopathic medications and disease exacerbations. Determinants of successful specific immunotherapy: 1. professionally trained health care professionals; 2. standardized allergen vaccines; 3. close cooperation and active participation of the patient throughout the treatment process.